neurological diseases

AChE-IN-27 is a small molecule used for high-throughput assays.

PRE-084 hydrochloride is a selective agonist of σ1(IC50:44 nM, in the sigma receptor assay).

TTA-A2 is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy.

Azelaprag (AMG 986) is an oral apelin receptor agonist (EC50 = 0.32 nM). Azelaprag may be used to treat neurological disorders, cardiovascular diseases, and obesity with metabolic syndrome.

CNS-5161 hydrochloride (CNS 5161A) is a small molecule antagonist and an NMDA receptor antagonist that selectively and non-competitively blocks the action of glutamate, and can be used for research on neurological diseases.

Deferoxamine (Desferrioxamine B) is an iron chelator. Deferoxamine can be used to reduce the accumulation and deposition of iron in tissues. Deferoxamine can improve neurological dysfunction by inhibiting ferroptosis and neuroinflammation after traumatic brain injury. It has antioxidant, anti-proliferation and anti-tumor activities, and can induce the production of HIF-1α, apoptosis and autophagy in cancer cells. It can be used to treat acute iron toxicity and COVID-19 related diseases.

Meclinertant (SR 48692) is a small-molecule compound and a neurotensin receptor-1 (NTSR1) antagonist with good selectivity and cell permeability. This compound can be used to study neurotensin signaling pathways and related neurological diseases, and serves as a potential diagnostic and therapeutic probe targeting NTSR1-positive tumors.

JNK-IN-8 (JNK Inhibitor XVI) is an effective JNK inhibitor that inhibits JNK1, JNK2, and JNK3 with IC₅₀ values of 4.7, 18.7, and 1 nM, respectively. JNK-IN-8 offers the advantages of minimal off-target activity, sustained inhibition, and high specificity. JNK-IN-8 primarily acts by blocking the JNK/c-Jun signaling pathway, inhibiting the phosphorylation of the downstream transcription factor c-Jun, thereby regulating the expression of genes associated with inflammatory responses, apoptosis, and stress responses. JNK-IN-8 can be used in research on tumors, inflammation, and neurological diseases.

EMD-503982 is an orally active, direct factor Xa (FXa) inhibitor that also exhibits inhibitory activity against factor VIIa, and has potential antithrombotic, anticancer, and neuroprotective effects. EMD-503982 can be used in research on thrombotic diseases.

1. Ginkgetin has anti-influenza virus and anti-fungal activities. 2. Ginkgetin has anti-inflammatory activity, can down-regulates COX-2 induction in vivo against skin inflammatory responses. 3. Ginkgetin is a good STAT3 inhibitor and may be a useful lead

MAO-B-IN-1 is a monoamine oxidase B inhibitor and can be used for the research of neurological diseases.

BAN ORL 24 is a highly potent nociceptin/orphan FQ (N/OFQ) receptor (NOP) antagonist that can be used to study neurological diseases.

H3 receptor antagonist 1 is used in the study of neurological diseases, histamine H3 receptor antagonist.

Kv3 modulator 1 is an imidazolidinedione-type orthosteric modulator of Kv3 voltage-gated potassium channels. Kv3 modulator 1 reverses mechanical hyperalgesia in rat models of neuropathic and inflammatory pain, with rapid onset and sustained, dose-dependent effects. Kv3 modulator 1 can be used to study the mechanisms underlying inflammatory pain and neurological disorders such as epilepsy and schizophrenia.

ROCK-IN-1, a potent ROCK inhibitor, effectively inhibits ROCK2-mediated signaling with an IC50 value of 1.2 nM. ROCK-IN-1 is applicable in the study of neurological disorders and inflammation-related diseases.

SPD-473 citrate (BTS 74398 citrate) is a dopamine reuptake inhibitor, a norepinephrine transporter protein (NET) inhibitor, and a 5-hydroxytryptamine reuptake inhibitor, and is used in the study of neurological disorders and endocrine and metabolic diseases.

3F8 is a selective GSK-3β inhibitor that can be used as a new tool and potential therapeutic candidate compound for GSK3-related diseases, and can be used in the study of neurological disorders and cancer.

Apadenoson is a potent Adenosine A2 receptor agonist with inhibitory effects on Adenosine A3 receptors with an IC of 45 nM. Apadenoson has anti-inflammatory activity and can be used to study neurological diseases.

Lifarizine FA is a sodium channel blocker used in the treatment of neurological disorders and cardiovascular diseases, study of stroke.

ReN-1869 is a novel selective histamine H(1) receptor antagonist with anti-neurogenic pain and anti-inflammatory activity for the study of neurological diseases.

Brefonalol HCl is an ADRA antagonist used in the treatment of neurological disorders and cardiovascular diseases and can be used in the study of angina pectoris, arrhythmias and hypertension.

ESP-31015 has potential anti-tumor and cholesterol-lowering activity and can be used to study cardiovascular and neurological diseases.

Imagabalin is an active compound used in the study of neurological diseases.

Lanicemine dihydrochloride (AZD-6765 dihydrochloride) is a low-capture NMDA channel blocker with antidepressant activity and can be used to study neurological diseases.